vimarsana.com

Latest Breaking News On - Tsx venture exchange czo - Page 1 : vimarsana.com

Ceapro Receives Final Court Approval for Merger with

TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (

United statesLou gehrigJenene thomasJoel shafferAeterna zentaris incCeapro incExchange commissionEuropean commissionToronto stock exchangeAnnual reportRegistration statementUnited states securities actInvestor contactMedia contactTsx venture exchange czoCeapro inc

Ceapro Inc Announces the Mailing of Meeting Materials in

EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro” or the “Company”) is pleased to announce that it.

United statesProvince of albertaAeterna zentariGilles gagnonAeterna zentarisJenene thomasKing bench of alberta the courtCeapro incData processing centreToronto stock exchangeBroadridge investor communications corporationAeterna zentaris incExchange commissionCompany the shareholdersCompany the boardCompany the

Ceapro Inc Reports 2023 Third Quarter and Nine-Month

– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology.

Beta glucanGilles gagnonJenene thomasProzesstechnologie gmbCorporate communications advisorExpanded technologyCorealis incClinical developmentManufacturing servicesMontreal heart instituteEnergy boosterMcmaster universityPipeline developmentCeapro incTechnology avenanthramidesAngiogenesis foundation

Ceapro to Present at the Virtual Investor 2023 Companies to

Live video webcast on Wednesday, January 18th at 3:00 PM ET.

Gilles gagnonGillesr gagnonJenene thomasCompanies to watch event onCorporate communications advisorJenene thomas communicationsCeapro incChief executive officerVirtual investorWatch eventThomas communicationsCorporate communicationsTsx venture exchange czoCeapro inc

Ceapro Inc Receives Approval from Health Canada to

- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the Montreal Heart.

Gilles gagnonJenene thomasGillesr gagnonJean claude tardifMontreal heart instituteCorporate communications advisorCorealis pharma incMontreal heart institute research centerMontreal health innovations coordinating centerJenene thomas communicationsCeapro incHealth canadaHealth innovations coordinating centerFirst in human studyAssess safetyMultiple ascending oral

vimarsana © 2020. All Rights Reserved.